^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Mekinist (trametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer

    Excerpt:
    ...Analysis of surgical specimens showed KRAS mutations and positive immunohistochemical staining of PD-L1 7....
    Trial ID:
    NCT02704156
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lancet Oncol
    Title:

    Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

    Published date:
    07/05/2021
    Excerpt:
    Eligible patients were aged 18 years or older with histologically confirmed pancreatic ductal adenocarcinoma characterised by mutant KRAS and positive immunohistochemical staining of PD-L1...Median overall survival was 24·9 months (23·3-26·5) with SBRT plus pembrolizumab and trametinib and 22·4 months (95% CI 21·2-23·6) with SBRT plus gemcitabine (hazard ratio [HR] 0·60 [95% CI 0·44-0·82]; p=0·0012).
    DOI:
    10.1016/S1470-2045(21)00286-2
    Trial ID:
    NCT02704156